Search Result

Results for "

cutaneous diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Akt (2) Bacterial (1) Calcium Channel (1) CDK (1) Glycosidase (1) IKK (2) Interleukin Related (3) Leukotriene Receptor (1) NF-κB (2) NO Synthase (2) p38 MAPK (2) Parasite (1) PGE synthase (1) PKC (2) Platelet-activating Factor Receptor (PAFR) (1) Protein Arginine Deiminase (2) Syk (1) TNF Receptor (1) Toll-like Receptor (TLR) (2) Tyrosinase (1) UGT (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (3) Infection (5) Inflammation/Immunology (9) Metabolic Disease (1) Neurological Disease (2)

By Targets:

Adrenergic Receptor (1)

Akt (2)

Bacterial (1)

Calcium Channel (1)

CDK (1)

Glycosidase (1)

IKK (2)

Interleukin Related (3)

Leukotriene Receptor (1)

NF-κB (2)

NO Synthase (2)

p38 MAPK (2)

Parasite (1)

PGE synthase (1)

PKC (2)

Platelet-activating Factor Receptor (PAFR) (1)

Protein Arginine Deiminase (2)

Syk (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (2)

Tyrosinase (1)

UGT (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (3)

Infection (5)

Inflammation/Immunology (9)

Metabolic Disease (1)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1181A

Pam2CSK4 TFA 1 Publications Verification	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .

HY-135304

PAD-IN-2	Protein Arginine Deiminase	Inflammation/Immunology Cancer
PAD-IN-2 is a potent pad4 inhibitor (IC₅₀: <1 μM). PAD-IN-2 can be used in the research of auto-immune diseases and cancers, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cystic fibrosis, asthma, multiple sclerosis and psoriasis .

HY-P1181

Pam2CSK4	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .

HY-10979

AN0128	Bacterial	Infection Inflammation/Immunology
AN0128 is a boron-containing antibacterial and anti-inflammatory agent. AN0128 against *S. aureus, S. epidermidis, P. acnes, B. subtilis* with minimum inhibitory concentration (MIC) values of 1, 0.5, 0.3, 1 μg/mL. AN0128 can be used for the research of periodontal disease and cutaneous diseases .

HY-N4267

Yangambin	Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human UGT1A1, and an IC₅₀ of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB₄-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca ²⁺ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .

HY-178227

KY19334	Wnt β-catenin CDK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes .

HY-115676

GSK199 analog hydrochloride	Protein Arginine Deiminase	Inflammation/Immunology
GSK199 analog hydrochloride belongs to a class of compounds that inhibit PAD4 (guanidinoarginine deiminase 4). GSK199 analog hydrochloride has potential uses in diseases including rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis .

HY-N18182

Mudanpioside E	Glycosidase	Inflammation/Immunology
Mudanpioside E is an orally effective paeoniflorin-type monoterpene glycoside antiallergic agent, with an IC₅₀ of 40.34 μM against IgE-mediated β-hexosaminidase release. Mudanpioside E reverses the inhibitory effect of the modified Xiaoqinglong Decoction extract (paeonia root component removed) on passive cutaneous anaphylaxis in mice. Mudanpioside E itself shows no activity against passive cutaneous anaphylaxis. Mudanpioside E can be used in research related to allergic diseases .

HY-183924

SYK-IN-14	Syk Tyrosinase	Inflammation/Immunology
SYK-IN-14 is an orally active Syk and ZAP-70 inhibitor with human Syk IC₅₀ of 0.006 μM, human ZAP-70 IC₅₀ of 0.23 μM. SYK-IN-14 functionally inhibits Syk kinase activity in vitro. SYK-IN-14 functionally inhibits ZAP-70 kinase activity in vitro. SYK-IN-14 suppresses passive cutaneous anaphylaxis reaction in Mus musculus mice. SYK-IN-14 suppresses Concanavalin A (HY-P2149)-induced IL-2 production in Mus musculus mice. SYK-IN-14 can be used for the research of allergic disorders and autoimmune diseases .

HY-W341759

1,4-Dihydrazinylphthalazine	Parasite	Infection
1,4-Dihydrazinylphthalazine (Compound 2) is an antiparasitic agent targeting Leishmania spp. 1,4-Dihydrazinylphthalazine is promising for research of tropical diseases, particularly cutaneous leishmaniasis .

HY-106390A

GYKI 12743	Adrenergic Receptor	Neurological Disease
GYKI 12743 is a vasoselective, postsynaptic α-adrenoceptor blocker. GYKI 12743 inhibits but does not completely eliminate the cutaneous microcirculatory blood flow reduction evoked by electrical stimulation of the peripheral stump of the cut saphenous nerve in rats. GYKI 12743 can be used for the study of neurological diseases .

Cat. No.	Product Name

HY-L114

Anti-inflammatory Traditional Chinese Medicine Active Compound Library	1,535 compounds
Inflammation promotes physiological and pathological processes by the activation of the immune system, local vascular system, and various cells within the damaged tissue. Accumulating epidemiological and clinical evidence shows that chronic inflammation is causally linked to various human diseases, including cerebrovascular, cardiovascular, joint, cutaneous, pulmonary, blood, liver, and intestinal diseases as well as diabetes. Various natural products from Traditional Chinese Medicine (TCM) have been shown to safely suppress proinflammatory pathways and control inflammation-associated disease. MCE designs a unique collection of 1,535 Traditional Chinese Medicine active compounds with anti-inflammatory activity, which are derived from Coptis chinensis, Radix isatidis, Flos Lonicerae, Forsythia suspensa, etc. MCE Anti-inflammatory Traditional Chinese Medicine Active Compound Library is a useful tool for discovery anti-inflammatory drugs from TCM.

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

1,535 compounds

Inflammation promotes physiological and pathological processes by the activation of the immune system, local vascular system, and various cells within the damaged tissue. Accumulating epidemiological and clinical evidence shows that chronic inflammation is causally linked to various human diseases, including cerebrovascular, cardiovascular, joint, cutaneous, pulmonary, blood, liver, and intestinal diseases as well as diabetes.

Various natural products from Traditional Chinese Medicine (TCM) have been shown to safely suppress proinflammatory pathways and control inflammation-associated disease. MCE designs a unique collection of 1,535 Traditional Chinese Medicine active compounds with anti-inflammatory activity, which are derived from Coptis chinensis, Radix isatidis, Flos Lonicerae, Forsythia suspensa, etc. MCE Anti-inflammatory Traditional Chinese Medicine Active Compound Library is a useful tool for discovery anti-inflammatory drugs from TCM.

Cat. No.	Product Name	Target	Research Area